CAS 1108743-60-7

Entrectinib

Description:

Entrectinib is a small molecule inhibitor primarily used in the treatment of certain types of cancer, particularly those with neurotrophic tyrosine receptor kinase (NTRK) gene fusions and rearrangements in the ROS1 and ALK genes. It functions by selectively inhibiting the activity of these tyrosine kinases, which play a crucial role in cell signaling pathways that promote tumor growth and survival. The compound is characterized by its ability to penetrate the blood-brain barrier, making it effective for treating central nervous system metastases. Entrectinib is typically administered orally and has a favorable pharmacokinetic profile, including a relatively long half-life, which allows for once-daily dosing. Its efficacy has been demonstrated in clinical trials, leading to its approval for use in specific patient populations. As with many targeted therapies, potential side effects may include fatigue, dizziness, and gastrointestinal disturbances, necessitating careful monitoring during treatment. Overall, Entrectinib represents a significant advancement in precision oncology, offering hope for patients with specific genetic alterations in their tumors.

Formula: C₃₁H₃₄F₂N₆O₂

InChI: InChI=1S/C31H34F2N6O2/c1-38-8-10-39(11-9-38)25-3-4-26(29(19-25)34-24-6-12-41-13-7-24)31(40)35-30-27-17-20(2-5-28(27)36-37-30)14-21-15-22(32)18-23(33)16-21/h2-5,15-19,24,34H,6-14H2,1H3,(H2,35,36,37,40)

InChI key: InChIKey=HAYYBYPASCDWEQ-UHFFFAOYSA-N

SMILES: N(C(=O)C1=C(NC2CCOCC2)C=C(C=C1)N3CCN(C)CC3)C=4C=5C(NN4)=CC=C(CC6=CC(F)=CC(F)=C6)C5

Synonyms:

• Entrectinib
• N-[5-[(3,5-Difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]benzamide
• NMS-E 628
• RXDX 101
• Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-
• N-(5-(3,5-difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide
• CS-1589
• Entrectinib(RXDX-101)
• NMS-E628
• Entrectinib,NMS-E628,RXDX-101
• NMS E628; RXDX-101;NMSE628; RXDX 101;NMS-E628; RXDX101
• entrecitinib
• Entrectinib(NMS-E628)

N-[5-[(3,5-Difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]benzamide

CAS: 1108743-60-7

Formula: C₃₁H₃₄F₂N₆O₂

Purity: 98%

Color and Shape: Solid

Molecular weight: 560.6375

Ref: IN-DA0039T4

N-(5-(3,5-Difluorobenzyl)-1H-Indazol-3-Yl)-4-(4-Methylpiperazin-1-Yl)-2-((Tetrahydro-2H-Pyran-4-Yl)Amino)Benzamide

CAS: 1108743-60-7

N-(5-(3,5-Difluorobenzyl)-1H-Indazol-3-Yl)-4-(4-Methylpiperazin-1-Yl)-2-((Tetrahydro-2H-Pyran-4-Yl)Amino)Benzamide

Purity: 98%

Molecular weight: 560.64g/mol

Ref: 54-PC108753

Entrectinib

CAS: 1108743-60-7

Entrectinib

Purity: ≥98%

Molecular weight: 560.64g/mol

Ref: 54-BUP13102

Entrectinib

CAS: 1108743-60-7

Formula: C₃₁H₃₄F₂N₆O₂

Color and Shape: White To Off-White Solid

Molecular weight: 560.65

Ref: 4Z-E-131001

Entrectinib

CAS: 1108743-60-7

Entrectinib (RXDX-101) is an orally Trk, ROS1, and ALK inhibitor. Entrectinib exhibits antitumor activity. Cost-effective and quality-assured.

Formula: C₃₁H₃₄F₂N₆O₂

Purity: 98.03% - 99.61%

Color and Shape: Solid

Molecular weight: 560.64

Ref: TM-T3678

Entrectinib

CAS: 1108743-60-7

Purity: 98%

Molecular weight: 560.6500244

Ref: 10-F862509